MedTrace Logo

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

NCT07768436 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-08-17

No results posted yet for this study

Summary

The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.

Conditions

Interventions

DRUG

CMF Regimen

CMF regimen: Cyclophosphamide, Methotrexate, and Fluorouracil

DRUG

Paclitaxel

Paclitaxel will be administered as an IV infusion into a peripheral or central vein.

Sponsors & Collaborators

Principal Investigators

  • Pamela Drullinsky, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-11
Primary Completion
2030-08-11
Completion
2030-08-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07768436 on ClinicalTrials.gov